Century Therapeutics reports FY2023 net loss $136.7M; cash $261.8M, runway into 2026

Century Therapeutics, Inc.

Net loss $136.7M in 2023 vs $131.0M in 2022; R&D expenses $92.7M, down from $97.2M.
Cash, cash equivalents and investments $261.8M as of Dec 31, 2023; net cash used in ops $88.3M.
Collaboration revenue from BMS agreement $2.2M in 2023, down from $5.2M in 2022.
One-time impairment charge of $16.4M from consolidating facilities in Philadelphia and Seattle.
FY2024 GAAP operating expense guidance $135M-$145M; cash runway expected into 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Century Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.

Period: the full year ended December 31, 2023
Result: reported results

Exact text from the filing

Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-034239

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.